Illuminating Tumour Biology: MammaPrint® and BluePrint® Genomic Insights from SABCS 2024 to Optimise Breast Cancer Care

This educational webinar was organised and sponsored by Agendia.
The speakers involved were compensated for their participation.

During this webinar, William Audeh, Joyce O’Shaughnessy, and Adam Brufsky review the latest MammaPrint and BluePrint data that was presented at SABCS 2024.

Topics covered include: 

• Prediction of adjuvant and neoadjuvant chemotherapy by MammaPrint 70-gene assay 
• Emerging data on the association of MammaPrint and CDK 4/6 inhibition 
• FLEX Study update: prospective, real-world, whole transcriptome early breast cancer study that links full genome profiling, including MammaPrint and BluePrint, paired with clinical information with a 10-year follow up 
• Utilising genomic insights from MammaPrint to inform NAC in T3 tumours 

Introduction to the San Antonio Breast Cancer Symposium (SABCS) 2024 Data [4:30]

MammaPrint® and BluePrint® Predict Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy (NAC) [16:46]

NAC for T3 Tumours [7:33]

FLEX Study Update – Real World Evidence (RWE), Full Transcriptome Study [4:42]

Prediction of Chemotherapy Benefit by MammaPrint [9:08]

Association of MammaPrint and CDK 4/6 Inhibition [10:18]

1. Chief Medical Officer, Agendia
2. Director of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA; and Chair of the Breast Disease Committee for Sarah Cannon Research Institute, Dallas, Texas, Oncology
3. Professor of Medicine, University of Pittsburgh School of Medicine; Director Emeritus of Comprehensive Breast Cancer Center; and Medical Director, Women’s Cancer Center, UPMC Magee Women’s Hospital, Pittsburgh, Pennsylvania, USA

References

1. Agendia. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (FLEX). NCT03053193. https://clinicaltrials.gov/study/NCT03053193.